

Special Report: Multi-Specialty Impact of COVID-19

Report Overview

To help stakeholders gauge the degree of impact that the COVID-19 pandemic is having on physicians, Spherix will begin ongoing coverage included in **Special Report: Multi-Specialty Impact of COVID-19**. A subscription to the **Special Report** will include a weekly deliverable of data collected from the prior week, with coverage beginning March 20 and continuing through mid-April, at which point the situation will be reassessed. **Specialty reports are available for:**



Survey Details

Each report will consist of feedback gathered from **50 specialists** geographically dispersed. A cross-specialty subscription is available upon request. **Content categories include:**

Demographics

- Specialty, patient volume, practice type, practice location, infusion capabilities, and clinical trial participation
- Nearby outbreak and related restrictions
- Personal travel to EU or China in past three months

Impact on practice

- Impact on practice
- Level of concern for patients
- Covering for partners
- Impact on clinical trial involvement
- Policies against travel/meetings
- Conference cancellations
- Restricting non-essential visits (industry, etc.)
- Implementation of telemedicine
- Preparedness for widespread local outbreak
- Appointment cancellations
- Rescheduling routine visits
- Overall impact to patient flow

Information on COVID-19

- Source(s) being used for your own information
- Most valuable information sources
- Contact with state health department
- How informed physicians feel about COVID-19 testing, guidelines, and treatment

Testing/screening

- Number requesting test
- Level of risk among requesting patients
- Number tested
- Number of positive/negative among those tested
- Logistics of testing
- Barriers to testing

Patients

- Percent at risk
- Characteristics of most at risk
- How well informed about true risks

Interaction with Industry

- Restrictions of in-person contact
- Recent industry contact methods
- Pharmaceutical industry support during outbreak
- Pharmaceutical company most active in addressing COVID-19 at national level / within personal practice

Opinions

- Overblown?
- Belief in being able to “flatten the curve”
- Satisfaction with how government handling
- Impact on supply chain for medication access
- Access to care from ER/ED or urgent care facilities
- Expected timeline for resolution?
- Government performance
- Willingness to try new products currently
- Willingness to initiate patients on therapy or change treatment
- Familiarity and anticipated utility of Gilead’s remdesivir against COVID-19
- Greatest concern related to COVID-19 (open end)

Specialty specific

- In immune, use of IL-6 inhibitors
- In MS, switching from or delaying next doses of immunosuppressant DMTs
- In migraine, use of newly approved therapy or anti-CGRP monoclonal antibodies
- In nephrology, impact in dialysis units



For information about pricing for **Special Report: Multi-Specialty Impact of COVID-19**, contact: info@spherixglobalinsights.com